Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/18/2025 | $75.00 | Overweight | Piper Sandler |
| 11/13/2025 | $45.00 | Buy | Jefferies |
| 10/27/2025 | $60.00 | Buy | Guggenheim |
| 10/13/2025 | $48.00 | Overweight | Barclays |
| 5/22/2025 | $44.00 | Buy | BTIG Research |
| 2/4/2025 | $20.00 | Outperform | Wolfe Research |
| 10/11/2024 | $49.00 | Buy | Stifel |
| 10/7/2024 | $45.00 | Buy | H.C. Wainwright |
4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
DENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech companies, Phase 2 is often the moment when science transitions from theory to validation. It is where investors, analysts, pharmaceutical partners, and institutional capital begin to separate promising platforms from speculative concepts. Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store That is why so much attention is focused on companies that are approaching pivotal readouts or are fresh off meaningful Phase 2 updates that could materially
MENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its presentation at the 2026 Jefferies Global Healthcare Conference, taking place in New York, NY from June 2-4, 2026. Presentation DetailsDate: Wednesday, June 3rd, 2026Presentation Time: 3:45PM ET A webcast and replay of Oruka's presentations will be available on the Oruka investor events website at https://ir.orukatx.com/news-events/events-presentations. About Oruka TherapeuticsOruka Therapeutics is de
ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected 2027 Post-offering cash, cash equivalents and marketable securities expected to fund Company through BLA for ORKA-001 MENLO PARK, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today reported first quarter 2026 financial results and provided a corporate upda
Piper Sandler initiated coverage of Oruka Therapeutics with a rating of Overweight and set a new price target of $75.00
Jefferies initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $45.00
Guggenheim initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $60.00
8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
10-Q - Oruka Therapeutics, Inc. (0000907654) (Filer)
8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
MENLO PARK, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the appointment of Chris Martin to its Board of Directors. Additionally, Cameron Turtle, DPhil, resigned from the Board effective December 11, 2025. "As we rapidly advance our co-lead programs through development, I'm pleased to announce this board transition at Oruka," said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics. "Chris's expertise can bring tremendous value to the compan
ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing, with longer-term EVERLAST-A data expected in 2H 2026 Management to host a conference call today at 8:00 a.m. ET MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced positive interim results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal ant
MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-A Phase 2a trial in moderate-to-severe plaque psoriasis on Monday, April 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast Details Oruka Therapeutics' live webcast of the EVERLAST-A results will begin on Monday, April 27th, at 8:00 a.m. ET. The live webcast can be accessed via
SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)
SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)
SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)